168 related articles for article (PubMed ID: 20160054)
1. Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.
Rullas J; García JI; Beltrán M; Cardona PJ; Cáceres N; García-Bustos JF; Angulo-Barturen I
Antimicrob Agents Chemother; 2010 May; 54(5):2262-4. PubMed ID: 20160054
[TBL] [Abstract][Full Text] [Related]
2. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
Chan CY; Au-Yeang C; Yew WW; Leung CC; Cheng AF
Antimicrob Agents Chemother; 2004 Jan; 48(1):340-3. PubMed ID: 14693563
[TBL] [Abstract][Full Text] [Related]
3. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.
Nuermberger EL; Yoshimatsu T; Tyagi S; Williams K; Rosenthal I; O'Brien RJ; Vernon AA; Chaisson RE; Bishai WR; Grosset JH
Am J Respir Crit Care Med; 2004 Nov; 170(10):1131-4. PubMed ID: 15306535
[TBL] [Abstract][Full Text] [Related]
4. The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
Iacobino A; Giannoni F; Pardini M; Piccaro G; Fattorini L
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010861
[TBL] [Abstract][Full Text] [Related]
5. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA
J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis.
Sulochana S; Mitchison DA; Kubendiren G; Venkatesan P; Paramasivan CN
J Chemother; 2009 Apr; 21(2):127-34. PubMed ID: 19423464
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Alvirez-Freites EJ; Carter JL; Cynamon MH
Antimicrob Agents Chemother; 2002 Apr; 46(4):1022-5. PubMed ID: 11897584
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Rodríguez JC; Ruiz M; López M; Royo G
Int J Antimicrob Agents; 2002 Dec; 20(6):464-7. PubMed ID: 12458143
[TBL] [Abstract][Full Text] [Related]
9. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.
Williams KN; Stover CK; Zhu T; Tasneen R; Tyagi S; Grosset JH; Nuermberger E
Antimicrob Agents Chemother; 2009 Apr; 53(4):1314-9. PubMed ID: 19075058
[TBL] [Abstract][Full Text] [Related]
10. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
Lechartier B; Hartkoorn RC; Cole ST
Antimicrob Agents Chemother; 2012 Nov; 56(11):5790-3. PubMed ID: 22926573
[TBL] [Abstract][Full Text] [Related]
11. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
Nuermberger E; Tyagi S; Tasneen R; Williams KN; Almeida D; Rosenthal I; Grosset JH
Antimicrob Agents Chemother; 2008 Apr; 52(4):1522-4. PubMed ID: 18285479
[TBL] [Abstract][Full Text] [Related]
12. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis.
Zhang M; Sala C; Hartkoorn RC; Dhar N; Mendoza-Losana A; Cole ST
Antimicrob Agents Chemother; 2012 Nov; 56(11):5782-9. PubMed ID: 22926567
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.
Guna R; Muñoz C; Domínguez V; García-García A; Gálvez J; de Julián-Ortiz JV; Borrás R
J Antimicrob Chemother; 2005 Jun; 55(6):950-3. PubMed ID: 15824090
[TBL] [Abstract][Full Text] [Related]
14. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
[TBL] [Abstract][Full Text] [Related]
15. Application of a microcalorimetric method for determining drug susceptibility in mycobacterium species.
Howell M; Wirz D; Daniels AU; Braissant O
J Clin Microbiol; 2012 Jan; 50(1):16-20. PubMed ID: 22090404
[TBL] [Abstract][Full Text] [Related]
16. Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis.
García-Tapia A; Rodríguez JC; Ruiz M; Royo G
Chemotherapy; 2004 Nov; 50(5):211-3. PubMed ID: 15523179
[TBL] [Abstract][Full Text] [Related]
17. A whole blood bactericidal assay for tuberculosis.
Wallis RS; Palaci M; Vinhas S; Hise AG; Ribeiro FC; Landen K; Cheon SH; Song HY; Phillips M; Dietze R; Ellner JJ
J Infect Dis; 2001 Apr; 183(8):1300-3. PubMed ID: 11262217
[TBL] [Abstract][Full Text] [Related]
18. [Present and future in the use of anti-tubercular drugs].
Didilescu C; Craiova UM
Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168
[TBL] [Abstract][Full Text] [Related]
19. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
[TBL] [Abstract][Full Text] [Related]
20. Treatment of tuberculosis. The Mitchell lecture 1979.
Mitchison DA
J R Coll Physicians Lond; 1980 Apr; 14(2):91-5, 98-9. PubMed ID: 6767845
[No Abstract] [Full Text] [Related]
[Next] [New Search]